|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: TMEM165 |
Gene summary for TMEM165 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | TMEM165 | Gene ID | 55858 |
| Gene name | transmembrane protein 165 | |
| Gene Alias | CDG2K | |
| Cytomap | 4q12 | |
| Gene Type | protein-coding | GO ID | GO:0000041 | UniProtAcc | Q9HC07 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 55858 | TMEM165 | C09 | Human | Oral cavity | OSCC | 2.56e-06 | 6.01e-01 | 0.1431 |
| 55858 | TMEM165 | LN22 | Human | Oral cavity | OSCC | 1.94e-18 | 1.86e+00 | 0.1733 |
| 55858 | TMEM165 | LN46 | Human | Oral cavity | OSCC | 4.38e-15 | 1.16e+00 | 0.1666 |
| 55858 | TMEM165 | LP15 | Human | Oral cavity | LP | 3.40e-06 | 1.49e+00 | 0.2174 |
| 55858 | TMEM165 | LP17 | Human | Oral cavity | LP | 1.20e-11 | 1.56e+00 | 0.2349 |
| 55858 | TMEM165 | EOLP-1 | Human | Oral cavity | EOLP | 2.30e-02 | 2.09e-01 | -0.0202 |
| 55858 | TMEM165 | NEOLP-2 | Human | Oral cavity | NEOLP | 2.03e-02 | 2.11e-01 | -0.0196 |
| 55858 | TMEM165 | NEOLP-3 | Human | Oral cavity | NEOLP | 6.01e-03 | 2.86e-01 | -0.0191 |
| 55858 | TMEM165 | SYSMH1 | Human | Oral cavity | OSCC | 2.05e-36 | 1.06e+00 | 0.1127 |
| 55858 | TMEM165 | SYSMH2 | Human | Oral cavity | OSCC | 7.62e-13 | 5.77e-01 | 0.2326 |
| 55858 | TMEM165 | SYSMH3 | Human | Oral cavity | OSCC | 1.57e-22 | 8.87e-01 | 0.2442 |
| 55858 | TMEM165 | SYSMH4 | Human | Oral cavity | OSCC | 7.89e-05 | 1.22e-01 | 0.1226 |
| 55858 | TMEM165 | HTA12-25-1 | Human | Pancreas | PDAC | 3.15e-03 | 5.59e-01 | 0.313 |
| 55858 | TMEM165 | HTA12-26-1 | Human | Pancreas | PDAC | 1.72e-03 | 4.48e-01 | 0.3728 |
| 55858 | TMEM165 | HTA12-29-1 | Human | Pancreas | PDAC | 8.32e-14 | 5.09e-01 | 0.3722 |
| 55858 | TMEM165 | GSM5252130_BPH340PrGF_Via | Human | Prostate | BPH | 1.78e-13 | 6.54e-01 | -0.1972 |
| 55858 | TMEM165 | GSM5252131_BPH340PrSF_Via | Human | Prostate | BPH | 3.76e-04 | 3.47e-01 | -0.2126 |
| 55858 | TMEM165 | GSM5252132_BPH389PrGF | Human | Prostate | BPH | 1.22e-02 | 8.22e-01 | -0.2247 |
| 55858 | TMEM165 | GSM5252133_BPH389PrSF | Human | Prostate | BPH | 7.63e-11 | 1.02e+00 | -0.2027 |
| 55858 | TMEM165 | GSM5252135_BPH511PrPUr_Fcol_3GEX | Human | Prostate | BPH | 2.95e-25 | 1.10e+00 | -0.1833 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Breast |  | IDC: Invasive ductal carcinoma |
| DCIS: Ductal carcinoma in situ | ||
| Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers | ||
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0072503 | Breast | Precancer | cellular divalent inorganic cation homeostasis | 42/1080 | 486/18723 | 5.91e-03 | 4.21e-02 | 42 |
| GO:00300046 | Breast | Precancer | cellular monovalent inorganic cation homeostasis | 13/1080 | 103/18723 | 6.26e-03 | 4.40e-02 | 13 |
| GO:00000412 | Breast | Precancer | transition metal ion transport | 13/1080 | 105/18723 | 7.35e-03 | 4.89e-02 | 13 |
| GO:000703314 | Esophagus | ESCC | vacuole organization | 127/8552 | 180/18723 | 1.04e-11 | 3.85e-10 | 127 |
| GO:000648714 | Esophagus | ESCC | protein N-linked glycosylation | 51/8552 | 65/18723 | 6.41e-08 | 1.13e-06 | 51 |
| GO:00091002 | Esophagus | ESCC | glycoprotein metabolic process | 226/8552 | 387/18723 | 2.64e-07 | 3.94e-06 | 226 |
| GO:00700854 | Esophagus | ESCC | glycosylation | 144/8552 | 240/18723 | 5.12e-06 | 5.38e-05 | 144 |
| GO:00070403 | Esophagus | ESCC | lysosome organization | 53/8552 | 74/18723 | 5.34e-06 | 5.57e-05 | 53 |
| GO:00801713 | Esophagus | ESCC | lytic vacuole organization | 53/8552 | 74/18723 | 5.34e-06 | 5.57e-05 | 53 |
| GO:00064865 | Esophagus | ESCC | protein glycosylation | 135/8552 | 226/18723 | 1.36e-05 | 1.24e-04 | 135 |
| GO:00434135 | Esophagus | ESCC | macromolecule glycosylation | 135/8552 | 226/18723 | 1.36e-05 | 1.24e-04 | 135 |
| GO:00091012 | Esophagus | ESCC | glycoprotein biosynthetic process | 181/8552 | 317/18723 | 2.54e-05 | 2.15e-04 | 181 |
| GO:00070332 | Liver | Cirrhotic | vacuole organization | 80/4634 | 180/18723 | 5.73e-09 | 2.25e-07 | 80 |
| GO:0007040 | Liver | Cirrhotic | lysosome organization | 35/4634 | 74/18723 | 2.10e-05 | 2.77e-04 | 35 |
| GO:0080171 | Liver | Cirrhotic | lytic vacuole organization | 35/4634 | 74/18723 | 2.10e-05 | 2.77e-04 | 35 |
| GO:00064873 | Liver | Cirrhotic | protein N-linked glycosylation | 30/4634 | 65/18723 | 1.40e-04 | 1.36e-03 | 30 |
| GO:0035751 | Liver | Cirrhotic | regulation of lysosomal lumen pH | 10/4634 | 16/18723 | 1.51e-03 | 9.91e-03 | 10 |
| GO:00300045 | Liver | Cirrhotic | cellular monovalent inorganic cation homeostasis | 38/4634 | 103/18723 | 4.02e-03 | 2.17e-02 | 38 |
| GO:00306415 | Liver | Cirrhotic | regulation of cellular pH | 31/4634 | 81/18723 | 4.76e-03 | 2.50e-02 | 31 |
| GO:00068853 | Liver | Cirrhotic | regulation of pH | 33/4634 | 91/18723 | 9.39e-03 | 4.29e-02 | 33 |
| Page: 1 2 3 4 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| TMEM165 | SNV | Missense_Mutation | novel | c.965N>G | p.Ser322Cys | p.S322C | Q9HC07 | protein_coding | deleterious(0.01) | benign(0.436) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
| TMEM165 | deletion | Frame_Shift_Del | novel | c.896delN | p.Thr299MetfsTer2 | p.T299Mfs*2 | Q9HC07 | protein_coding | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | ||
| TMEM165 | SNV | Missense_Mutation | c.235C>T | p.His79Tyr | p.H79Y | Q9HC07 | protein_coding | tolerated(0.05) | benign(0.089) | TCGA-EK-A2RJ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| TMEM165 | SNV | Missense_Mutation | novel | c.421N>G | p.Thr141Ala | p.T141A | Q9HC07 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AA-3715-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
| TMEM165 | SNV | Missense_Mutation | c.842C>T | p.Thr281Met | p.T281M | Q9HC07 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AA-3821-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| TMEM165 | SNV | Missense_Mutation | rs752610788 | c.919N>A | p.Val307Ile | p.V307I | Q9HC07 | protein_coding | deleterious(0.01) | probably_damaging(0.939) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR |
| TMEM165 | SNV | Missense_Mutation | rs200205156 | c.617G>A | p.Arg206Gln | p.R206Q | Q9HC07 | protein_coding | tolerated(0.08) | possibly_damaging(0.467) | TCGA-EI-6917-01 | Colorectum | rectum adenocarcinoma | Male | <65 | III/IV | Chemotherapy | 5fluorouracil+oxaciplatina+l-folinian | SD |
| TMEM165 | insertion | Frame_Shift_Ins | novel | c.505_506insT | p.Gly171TrpfsTer3 | p.G171Wfs*3 | Q9HC07 | protein_coding | TCGA-G4-6302-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| TMEM165 | SNV | Missense_Mutation | novel | c.316N>A | p.Val106Ile | p.V106I | Q9HC07 | protein_coding | tolerated(0.1) | possibly_damaging(0.705) | TCGA-A5-A1OF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| TMEM165 | SNV | Missense_Mutation | novel | c.643N>T | p.Asp215Tyr | p.D215Y | Q9HC07 | protein_coding | deleterious(0) | probably_damaging(0.99) | TCGA-AP-A1DV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |